Literature DB >> 7581090

Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation.

T Demirer1, T Gooley, C D Buckner, F B Petersen, K Lilleby, S Rowley, J Sanders, R Storb, F R Appelbaum, W I Bensinger.   

Abstract

This retrospective study was conducted to determine whether the total number of nucleated cells (TNC)/kg collected at marrow harvest was associated with outcome in 151 patients with acute myelogenous leukemia (AML) who received an autologous purged (n = 67) or non-purged (n = 84) marrow transplant. At the time of transplant 33 patients were in first complete remission (CR), 47 in second CR, 54 in first relapse and 17 beyond second CR. Ninety patients received busulfan (BU) 16 mg/kg and cyclophosphamide (CY) 120 or 200 mg/kg, 51 patients received CY 120 mg/kg and total body irradiation (TBI) 12-15.75 Gy and 10 patients received BU 8 mg/kg, CY 60 mg/kg and TBI 12 Gy as conditioning regimens. Patients whose marrow harvest yielded < 2 x 10(8) TNC/kg did not undergo purging with 4-hydroperoxycyclophosphamide (4HC). This group of patients (n = 28) had a 100 day mortality of 50% and only 54% achieved a granulocyte levels of > 0.5 x 10(9)/l and 29% achieved platelet transfusion independence. Patients whose marrow harvest yielded 2-4 x 10(8) TNC/kg and did not undergo marrow purging had a 20% mortality by day 100, 91% recovered granulocytes to > 0.5 x 10(9)/l and 61% became platelet independent. Patients whose marrow harvest yielded 2-4 x 10(8) TNC/kg and underwent marrow purging with 4HC had a 50% mortality by day 100 and 58% achieved a granulocyte levels of > 0.5 x 10(9)/l and 42% became platelet transfusion independent.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581090

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

Review 1.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

Review 2.  A review of infectious complications after haploidentical hematopoietic stem cell transplantations.

Authors:  Erden Atilla; Pinar Ataca Atilla; Sinem Civriz Bozdağ; Taner Demirer
Journal:  Infection       Date:  2017-04-17       Impact factor: 3.553

Review 3.  Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation.

Authors:  Erden Atilla; Pınar Ataca Atilla; Güldane Cengiz Seval; Mehmet Bektaş; Taner Demirer
Journal:  Turk J Gastroenterol       Date:  2019-02       Impact factor: 1.852

Review 4.  Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer.

Authors:  Nuri Karadurmus; Ugur Sahin; Bilgin Bahadir Basgoz; Fikret Arpaci; Taner Demirer
Journal:  World J Transplant       Date:  2016-12-24

Review 5.  Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.

Authors:  Erden Atilla; Selami K Toprak; Taner Demirer
Journal:  Turk J Haematol       Date:  2016-12-12       Impact factor: 1.831

Review 6.  A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.

Authors:  Erden Atilla; Pınar Ataca Atilla; Taner Demirer
Journal:  Balkan Med J       Date:  2017-01-05       Impact factor: 2.021

Review 7.  A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer.

Authors:  Nuri Karadurmus; Ugur Sahin; Bilgin Bahadir Basgoz; Fikret Arpaci; Taner Demirer
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-04-01

Review 8.  Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation.

Authors:  Güldane Cengiz Seval; Pervin Topçuoğlu; Taner Demirer
Journal:  Balkan Med J       Date:  2018-03-15       Impact factor: 2.021

9.  Long-term outcome in acute myelogenous leukemia autografted with mafosfamide-purged marrow in a single institution: adverse events and incidence of secondary myelodysplasia.

Authors:  A Abdallah; G Egerer; R M Weber-Nordt; M Körbling; R Haas; A D Ho
Journal:  Bone Marrow Transplant       Date:  2002-07       Impact factor: 5.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.